Vastera

Vastera is a biotech startup pioneering innovative treatments for cardiovascular and cancer diseases through novel redox signaling pathways. Founded by SangWon Kang, a professor at Ewha Womans University, in 2018, the company is focused on creating "first-in-class" therapies in these medical areas, leveraging research on redox signaling in blood vessels and cancer. The company's mostrecent funding round was a KRW18.00B Series B investment on 02 March 2022, with participation from a diverse group of investors including SJ Investment Partners, Partners Investment, Daesung Private Equity, UTC 2019 BioVentureFund, ID Ventures, Medytox Venture Investment, Shinan Venture Investment, and Medici Investment. Vastera's focus on biotechnology and healthcare positions it at the intersection of cutting-edge medical research and high-potential market opportunities. With a strong founding team and impressive investor backing, the company is poised to make meaningful advancements in the treatment of cardiovascular and cancer diseases utilizing innovative approaches to redox signaling.